NCT00046371View on ClinicalTrials.gov

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2002

Study Completion Date

August 31, 2005

Conditions
Breast Neoplasms
Interventions
DRUG

THERATOPE® vaccine

Trial Locations (17)

Unknown

Berkeley

San Francisco

Santa Monica

Jacksonville

Plantation

Port Saint Lucie

Chicago

Des Moines

Billings

Morristown

Gastonia

Hickory

Cincinnati

Columbus

Houston

Norfolk

Richmond

All Listed Sponsors
lead

Oncothyreon Canada Inc.

INDUSTRY

NCT00046371 - Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter